Fresenius SE & Co. KGaA (ETR:FRE)

Germany · Delayed Price · Currency is EUR

42.90

-0.26 (-0.60%)

May 12, 2025, 5:35 PM CET

49.63% (1Y)

Market Cap	24.16B
Revenue (ttm)	22.13B
Net Income (ttm)	422.00M
Shares Out	563.24M
EPS (ttm)	0.75
PE Ratio	20.22
Forward PE	12.60
Dividend	1.00 (2.33%)
Ex-Dividend Date	May 26, 2025

Volume	997,721
Average Volume	1,147,735
Open	43.58
Previous Close	43.16
Day's Range	42.63 - 43.58
52-Week Range	27.26 - 44.06
Beta	0.96
RSI	67.28
Earnings Date	May 7, 2025

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; e... [Read more]

Industry Medical Care Facilities

Sector Healthcare

Founded 1912

Employees 176,486

Stock Exchange Deutsche Börse Xetra

Ticker Symbol FRE

Full Company Profile

Financial Performance

Financial Statements

News

Fresenius medical care outlines 2025 operating income growth targets amid strategic transformations

4 days ago - Seeking Alpha

Fresenius SE & Co. KGaA 2025 Q1 - Results - Earnings Call Presentation

5 days ago - Seeking Alpha

Fresenius SE & Co. KGaA (FSNUF) Q1 2025 Earnings Call Transcript

5 days ago - Seeking Alpha

Fresenius SE & Co. KGaA reports Q1 results

5 days ago - Seeking Alpha

Fresenius posts profit beat in first quarter, confirms outlook

German healthcare group Fresenius beat analysts' adjusted operating profit expectations for the first quarter on Wednesday, citing a strong performance at its drug making division Kabi.

6 days ago - Reuters

Fresenius: Holding On For Longer-Term Growth Driven By Demand In Kidney Care Segment

15 days ago - Seeking Alpha

EQS-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 23.05.2025 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution

EQS-News: Fresenius SE & Co. KGaA / Announcement of the Convening of the General Meeting Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 23.05.202...

4 weeks ago - Wallstreet:Online

Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps

Pacira BioSciences, Inc . (NASDAQ: PCRX) on Monday settled its litigations with Fresenius Kabi USA , Jiangsu Hengrui Pharmaceuticals Co ., Ltd., and eVenus Pharmaceuticals Laboratories, Inc . related...

4 weeks ago - Benzinga

Pacira surges on patent settlement with Fresenius

5 weeks ago - Seeking Alpha

EQS-PVR: Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EQS Voting Rights Announcement: Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe...